Post-Marketing Surveillance on the Long-Term Use of Prazaxa Capsules in Patients With Nonvalvular Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Atrial fibrillation; Embolism and thrombosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 18 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
- 18 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.